ArticleCureus2025
Impact of the 2022 American Academy of Pediatrics Hyperbilirubinemia Guideline on Phototherapy Utilization in a Resource-Limited Setting: A Single-Center Pre-Post Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical, economic, and organisational impact of the novel AAP 2022 neonatal hyperbilirubinemia guidelines in an Italian third-level neonatology unit.European journal of pediatrics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The 2022 American Academy of Pediatrics (AAP) clinical practice guideline for neonatal hyperbilirubinemia raised phototherapy and exchange transfusion thresholds to minimize overtreatment. The real-world effect of these changes in resource-limited Indian settings remains unclear. This study aimed to evaluate the potential reduction in phototherapy use and validate the safety of the 2022 guideline. Methodology This single-center, quasi-experimental, pre-post study was conducted at Subbaiah Institute of Medical Sciences, Shivamogga, India. In part 1 (retrospective simulation), data from 100 consecutive term neonates (≥38 weeks' gestation) without neurotoxicity risk factors who received phototherapy under the 2004 AAP guideline were re-analyzed using the 2022 thresholds. In part 2 (prospective validation), another cohort of 100 consecutive term neonates without risk factors was prospectively managed using the 2022 guideline. Primary outcomes were phototherapy rate and readmission for jaundice within 14 days. Results Of 100 infants treated per the 2004 guideline, 54 (54%) had bilirubin levels below the 2022 phototherapy threshold and would not have required treatment. In the prospective 2022 cohort, only nine (9%) required phototherapy. No infant (0%) required readmission for jaundice. Conclusions Implementation of the 2022 AAP guideline reduced phototherapy use by over 50% compared to the 2004 criteria, without compromising safety. Adoption of the updated guideline in resource-limited settings can prevent unnecessary treatment, conserve resources, and support family-centered neonatal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.